We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Blood Parameter Analysis Establish Prognosis for Brain Metastases Patients

By LabMedica International staff writers
Posted on 07 Oct 2015
Certain laboratory results, which have previously not been used specifically for this purpose, can help to predict survival in patients with newly diagnosed brain metastases and to decide on the most appropriate treatment strategy.

Brain metastases are secondary tumors that have spread from primary tumors at other sites in the body such as lungs, breast or skin, for example. More...
Approximately 40% of all patients with metastasized cancer develop metastases in their brain.

Scientists at the Medical University of Vienna (Austria ) conducted a study which included 1,201 patients with different primary cancers. They analyzed blood parameters that had not so far been included in oncological prognosis scores. The results show that subnormal levels of red blood pigment (hemoglobin), blood platelets (thrombocytes), white blood cells (leucocytes) and albumin (the main plasma protein) and elevated levels of serum creatinine, lactate dehydrogenase and the inflammatory markers C-reactive protein (CRP) were associated with poorer survival from brain metastases.

The commonest type of malignant brain tumors, are difficult to treat, often cause severe symptoms, such as intense headaches, neurological problems or epilepsy and are often associated with a limited life expectancy. Nevertheless, there are some patients who survive for a long time, despite their brain metastases. Anna Sophie Berghoff, PhD, the lead author of the study, said, “We asked ourselves whether there are any objective parameters that can provide us with a more stable basis for establishing an accurate prognosis for patients. This is not only important for estimating their life expectancy or for their inclusion in clinical studies but also for deciding on the most appropriate treatment for them.”

Dr. Berghoff, added, “This study has enabled us to show that the investigated parameters have a strong, independent prognostic impact and are therefore to be regarded as objective parameters. This is particularly true of hemoglobin levels and the concentration of CRP and lactate dehydrogenase." The team is now recommending that the last three parameters, in particular, be tested in follow-up studies for inclusion in prognosis scores. The study was presented at the European Cancer Congress ECC2015, held September 25–29, 2015, in Vienna (Austria).

Related Links:

Medical University of Vienna 



New
Gold Member
Automated MALDI-TOF MS System
EXS 3000
Portable Electronic Pipette
Mini 96
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Human Estradiol Assay
Human Estradiol CLIA Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: When assessing the same lung biopsy sample, research shows that only 18% of pathologists will agree on a TCMR diagnosis (Photo courtesy of Thermo Fisher)

Molecular Microscope Diagnostic System Assesses Lung Transplant Rejection

Lung transplant recipients face a significant risk of rejection and often require routine biopsies to monitor graft health, yet assessing the same biopsy sample can be highly inconsistent among pathologists.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.